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Abstract
Background: The Gram-negative pathogen Bordetella bronchiseptica causes acute and chronic respiratory infection
in a variety of animals. Currently, there is no vaccine to prevent these infections. To identify useful candidate
antigens for such a vaccine, five B. bronchiseptica genes including amino acid ATP-binding cassette transporter
substrate-binding protein (ABC), lipoprotein (PL), outer membrane porin protein (PPP), leu/ile/val-binding protein
(BPP), and conserved hypothetical protein (CHP) were cloned and the recombinant proteins were expressed. The
immune responses of mice to vaccination with individual recombinant proteins were measured.
Results: Each of the tested recombinant proteins induced a high antibody titer. PPP and PL showed protective
indices against challenges with B. bronchiseptica. The protection ratios were 62.5 and 50 %, respectively, compared
with 12.5 % for control vaccinations. The protection ratios of ABC, BPP, and CHP were not significantly different
from the controls. IgG-subtype and cytokine analysis demonstrated that PPP and PL can induce two immune
responses: a humoral immune response and a cell-mediated immune response. The humoral immunity-mediated,
Th2-type response dominated.
Conclusion: The identification of PPP and PL, which offer immune-protective potential, identifies them as
candidates for the development of a diagnostic test or a vaccine for B. bronchiseptica.
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Background
Bordetella bronchiseptica is an important bacterial
pathogen that causes a number of respiratory diseases in
livestock and poultry. B. bronchiseptica can colonize the
host for its entire lifetime, resulting in great economic
losses worldwide. Examples of diseases caused by B.
bronchiseptica include atrophic rhinitis in swine, kennel
cough in dogs, and snuffles in rabbits [1]. B. bronchisep-
tica infections are often endemic in commercial rabbit-
ries, where they and difficult to control due to the rapid
spread and persistence of the infection [2]. Although
many available B. bronchiseptica vaccines induce high
titers of serum antibodies and offer protection against
severe diseases [3], B. bronchiseptica is often isolated
from animals in vaccinated populations, suggesting that
the vaccines are not satisfactory in terms of efficacy and
safety [4, 5].
The development of a new vaccine is critical to the
prevention and control of B. bronchiseptica infection. To
identify useful B. bronchiseptica antigen candidates for
use in new diagnostics or vaccines, we previously perfor-
med immunoproteomic analyses to analyze the outer
membrane proteins of B. bronchiseptica and identified a
total of 14 common immunoreactive proteins [6]. Here,
we selected five of these newly discovered immunogenic
proteins as targets for recombinant prokaryotic expres-
sion. We tested the recombinant proteins for immunogen-
icity and protection against B. bronchiseptica in mice to
find novel immune-protective antigens.
Methods
Bacteria and mice
B. bronchiseptica strain HB was isolated from a rabbit
with infectious rhinitis. The bacteria were cultured on
sheep blood agar (Hangzhou Tianhe Microorganism
Reagent Co, Ltd) and in tryptone soya broth (TSB,
Oxoid, Basingstoke, England, UK) containing 5 % bovine
calf serum in a rotary incubator shaker at a speed of
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200 rpm at 37 °C for the extraction of DNA. Female ICR
mice (18–22 g) were purchased from the Zhejiang
Experimental Animal Center (China) and maintained
under standard conditions. All animal protocols were
approved by the Institutional Animal Care and Use
Committee of Animal Husbandry and Veterinary Institute,
Zhejiang Academy of Agricultural Sciences. Experiments
were performed in accordance with the Regulations for
the Administration of Affairs Concerning Experimental
Animals (China, 1988) and the Standards for the Adminis-
tration of Experimental Practices (Zhejiang, China, 2009).
All surgeries were performed in accordance with the
recommendations proposed by the European Commis-
sion (1997), and efforts were made to minimize animal
suffering.
Antigen probability, gene amplification, cloning, and
sequencing
Five proteins including amino acid ATP-binding cassette
transporter substrate-binding protein (ABC), lipoprotein
(PL), outer membrane porin protein (PPP), leu/ile/val-
binding protein (BPP), and conserved hypothetical
protein (CHP) were selected as targets on the basis of
previous studies. The reference sequences were analyzed
using VaxiJen v.2.0 (http://www.ddg-pharmfac.net/vaxijen/
VaxiJen/VaxiJen.html) to determine their antigenic prob-
ability. VaxiJen makes antigenic predictions based on the
physicochemical properties of proteins without consider-
ing their sequence alignments. Accuracy of its predictions
is 70–89 % [7]. A threshold value >0.4 was considered im-
perative for further analysis.
To generate expression constructs for the candidate
proteins, five pairs of specific primers were designed
(Table 1) to amplify the corresponding genes. Restriction
sites (underlined) for Nco I and Xho I were added at the
5′ end of each forward and reverse primer, respectively.
Target genes encoding the mature, full-length proteins
without signal peptide sequences were amplified by
PCR, digested with Nco I and Xho I, and ligated to a
pET32a + vector. Correct constructs were confirmed
using DNA extraction by alkaline lysis, followed by
double digestion and sequencing.
Expression and purification of recombinant proteins
The verified constructs were transformed into Escherichia
coli BL21 cells (DE3, Shanghai, China) for protein ex-
pression. Expression of the recombinant proteins was
completed according to the manufacturer’s instructions.
Briefly, the recombinant proteins were produced as inclu-
sion bodies and purified under denaturing conditions.
Purity of the recombinant proteins was determined using
5 % stacking/12 % resolving SDS polyacrylamide gel elec-
trophoresis followed by western blot analysis. The recom-
binant proteins from non-stained gels were transferred to
polyvinylidene fluoride membranes with a semidry trans-
fer apparatus for 45 min at 16 V. Next, the membranes
were blocked by incubation with 5 % nonfat milk in
phosphate-buffered saline-Tween (PBST) (pH 7.4) over-
night at 4 °C. After three washes with PBST, the mem-
branes were incubated with pooled convalescent sera
diluted with PBST (1:1000) containing 1 % nonfat milk
under gentle agitation at room temperature for 1 h [6].
The membranes were then rinsed in PBST for 15 min and
exposed to goat anti-rabbit IgG-horseradish peroxidase
(1:5000). Incubation was performed for 1 h at room
temperature. The membrane was then washed with PBST
three times for 10 min and developed with diaminoben-
zine for 3 to 5 min to optimize the image.
Immune responses of mice to recombinant protein
vaccination
A total of 48 ICR mice were divided into six groups. Five
groups were inoculated with the recombinant proteins
(50 μg/dose), respectively, in a 200 μL volume mixed
with Freund’s complete adjuvant. A pre-experiment
was carried out to define the dose, and we found that
Table 1 The primer sequences used to amplify the selected proteins
Primer name Sequence (5′-3′) Target gene (reference Gene ID) PCR amplicon size
ABC-F GCGCCATGGGCAAGAAAATCACCGCTGTA ABC (ID:2660093) 789 bp
ABC-R TATCTCGAGCTTGATGATGTTGGCGCCGAA
BPP-F GCGCCATGGGCAACAAGGCATTTCGTTTC BPP (ID: 2663902) 1125 bp
BPP-R GCGCTCGAGTTACTTGTACGACGTCTTGCT
CHP-F TATCCATGGGCTATCCCAACCGCCGGCTGTAC CHP (ID: 2660968) 573 bp
CHP-R TATCTCGAGCTACTTGCCGCGCCCGCCTTG
PL-F GCGCCATGGGCCGTATGAACAAACGTCAT PL (ID: 2662792) 1125 bp
PL-R GCGCTCGAGTCAGACCATCTTGTCCTTCAG
PPP-F GCGCCATGGGCAAAAAGACTCTGCTCGCT PPP (ID: 2660513) 1164 bp
PPP-R GCGCTCGAGTTAGAAGCGGTGACGGATACC
The restriction sites are underlined
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immune efficacy of 50 μg/dose rPL was better than
25 μg/dose. A control group was inoculated with
200 μL PBS. Each group was inoculated twice at a 2-week
interval. Two weeks after the second inoculation, the mice
were challenged intraperitoneally with 1.74 × 107 CFU of
B. bronchiseptica HB (LD50 = 2.42 × 10
6 CFU). Prior to
challenge, serum was collected from each mice via tail
bleeding. Antibody titers were measured using indirect
enzyme-linked immunosorbent assay (ELISA). Briefly, the
purified recombinant proteins were diluted to 1 μg/mL in
carbonate–bicarbonate buffer (pH 9.6) and used to coat
the wells of a polystyrene plate (100 μL/well). The plates
were blocked with 5 % skim milk and incubated with sera
from the inoculated mice (1:100 dilutions). The bound
antibodies were detected by anti-mouse IgG (1:5000)
HRP-conjugated secondary antibody (Abcam, Cambridge,
UK) and immune complexes were revealed using the
TMB substrate. The antibody responses to the immuniza-
tions were determined based on measuring the absorb-
ance at 450 nm in an ELISA reader (Bio-Rad, USA). The
protective efficacy was determined by mouse survival up
to 10 days post challenge. For the acquired immune-
protective proteins, further tests were conducted to deter-
mine antibody subtypes IgG1 and IgG2a. To evaluate IgG
subclasses (IgG1 and IgG2a), an indirect ELISA was per-
formed similarly to the previous ELISA of IgG. Sera from
mice were assessed individually, and all reactions were
performed in triplicate.
Splenocyte proliferation and cytokine analysis of
immune-protective proteins
Mice (3 mice/group) were injected with two doses (day 0, 14)
of the immune-protective protein rPPP and rPL (50 μg/dose)
in a 200 μL volume mixed with Freund’s complete adju-
vant, a control group (n = 3) was inoculated with
200 μL PBS. All mice of each group were sacrificed
under ethyl ether anesthesia 3 weeks after the second
inoculation, splenocyte suspensions were prepared and
used for lymphocyte proliferation testing (determined
by the MTT method). Briefly, 5 × 106 cells/well were
cultured in 96-well plates in DMEM supplemented with
10 % FCS. Cells were stimulated with the individual re-
combinant proteins (10 μg/mL) or medium alone
(negative control) at 37 °C with 5 % CO2. After 68 h,
20 μL 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazo-
lium bromide (MTT, Sigma, St. Louis, US) solution
(5 mg/mL) was added to each well and incubated for
4 h. The supernatant fraction of each well was dis-
carded and 100 μl DMSO was added to each well. Ab-
sorbance was read at 570 nm using an ELISA reader.
The stimulation index (SI) was calculated for each sam-
ple. SI is defined as the ratio of the average OD570 value
samples containing antigen-stimulated cells to the average
OD570 value of the control cells cultured in medium alone.
For the detection of cytokine responses to the acquired
immune-protective proteins, splenocytes from the immu-
nized mice were cultured with each recombinant protein
as described in the lymphocyte proliferation assay. The
concentrations of interleukin-2 (IL-2), IL-4, IL-10, and
interferon-gamma (IFN-γ) were measured using a com-
mercial ELISA kit according to the manufacturer’s instruc-
tions (R&D, USA). All assays were performed in triplicate.
Statistical analysis
All data were reported as the mean ± standard error. To
determine the significance of the observations, Student’s
t-tests were carried out using the SPSS 17.0 software
(SPSS Inc., Chicago, US). P values ≤ 0.05 were considered
statistically significant.
Results
Antigen probability, cloning, expression, and purification
of recombinant proteins
The antigenicities of the five proteins were predicted as fol-
lows: ABC, 0.6470; BPP, 0.6318; CHP, 0.4716; PL, 0.6523;
PPP, 0.6024. Hence, each protein was considered a possible
protective antigen and subunit vaccine. The results of the
double digestions of the positive plasmids containing the five
selected proteins are shown in Fig. 1. Sequence analysis
showed that the homology between the amplified genes and
the corresponding reference sequences reached more than
97 %, which was consistent with the deduced amino acid se-
quences. The stripe sizes of the proteins after the plasmids
were transformed and expressed in E. coli BL21 (DE3) were:
rABC, 56.6 KDa; rBPP, 39.7 KDa; rCHP, 21.6 KDa; rPL, 41.5
KDa; rPPP, 41.3 KDa. The recombinant fusion proteins were
expressed mainly as insoluble proteins. Thus, the recombin-
ant proteins were solubilized using 8 M urea in lysis buffer.
Immunoblot analysis indicated that the recombinant
proteins reacted with convalescent sera against
Fig. 1 PCR amplification of the target genes from B. bronchiseptica.
The lanes in the image are as follows: M, DL2000 DNA marker. 1,
amplified PPP gene product. 2, amplified BPP gene product. 3, amplified
PL gene product. 4, amplified CHP gene product. 5, amplified ABC gene
product. 6, negative control
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B. bronchiseptica HB but did not react with negative
control serum from uninfected rabbits (Fig. 2).
Immune responses of mice to recombinant protein
vaccination
The antibody titers of mice vaccinated with the recombin-
ant proteins were determined (Fig. 3a). There was a signifi-
cant increase (P < 0.005) in antibodies to the recombinant
proteins on day 17 before B. bronchiseptica challenge for
groups 1, 2, 3, 4, and 5 compared with the control (group
6). Up to 10 days after challenge with B. bronchiseptica HB,
rPPP and rPL provided better protection [protection ratio
of 62.5 % (5/8) and 50 % (4/8), respectively] compared with
PBS alone [protection ratio of 12.5 % (1/8); Fig. 4]. No sta-
tistically significant differences were observed between the
protection ratios of rABC (1/8), rBPP (2/8), or rCHP (1/8),
and that of the PBS control. Viable B. bronchiseptica was
recovered from all the mice that died. For the acquired
immune-protective rPPP and rPL, further tests were con-
ducted to determine antibody subtypes. Mice immunized
with rPPP produced high titers of specific IgG1 and IgG2a
antibodies. The specific IgG1 titer was higher than the spe-
cific IgG2a titer (IgG1:IgG2a = 1.38) (Fig. 3b). The mice im-
munized with rPL mainly produced high titers of IgG1 but
low titers of IgG2a (IgG1:IgG2a = 4.2) (Fig. 3b). Examin-
ation of IgG subclasses showed that mice responded to re-
combinant proteins with a Th2-type immune response,
which is associated with the stimulation of high IgG1 anti-
bodies and low titres of IgG2, indicating a stronger humoral
response.
Splenocyte proliferation and cytokine analysis of
immune-protective proteins
Lymphocyte proliferation assays showed that rPPP and
rPL effectively stimulated lymphocyte proliferation
(Table 2). Levels of IFN-γ, IL-2, and IL-4 were signifi-
cantly increased after stimulation by rPPP and rPL. rPL
enhanced IL-10 production. rPPP had no significant
effect on IL-10 production. The detection of cytokines
showed that rPPP and rPL each induced both a humoral
immune response and a cell-mediated immune response
in the immunized mice.
Discussion
B. bronchiseptica is an important pathogen responsible
for infectious rhinitis in rabbits, as well as diseases in
other animals. The protective effectiveness of the B.
bronchiseptica vaccine currently used is not satisfactory.
Therefore, the identification of antigenic proteins for a
new vaccine is urgently needed. Subunit vaccines are
attractive and useful tools for the development of
protective immunity against pathogenic microorganisms
[7, 8]. A number of B. bronchiseptica outer membrane
proteins have been identified, including filamentous
hemagglutinin, pertussis adhesin, adenylyl cyclase hemoly-
sin, tracheal colonization factor, iron-regulating outer
membrane protein, outer membrane protein A, lipopro-
tein, and others. Among these proteins, filamentous
hemagglutinin and the outer membrane protein pertactin
are factors important for attachment during infection.
They also serve as protective immunogens and are among
the most important components of acellular vaccines for
whooping cough [9]. Previously, our immunoproteomics
approach helped us identify 14 common immunogenic
B. bronchiseptica proteins [6]. Five of those proteins
(three putative proteins, ABC, CHP, and PL) were
selected and successfully expressed in a recombinant
prokaryotic expression system. Western blot analysis
indicated that all five recombinant proteins were im-
munogenic in mice, inducing high antibody titers.
Fig. 2 Expression and western blot analysis of recombinant target proteins. Lanes are as follows: Lane M, protein molecular weight marker. Lanes
1–2, 4–5, 7–8, 10–11, 13–14: CBB staining of the recombinant E. coli whole-cell lysate before and after induction with IPTG for recombinant ABC,
BPP, PPP, PL, and CHP, respectively. Lanes 3, 6, 9, 12, 15: purified recombinant ABC, BPP, PPP, PL, and CHP, respectively. Lanes 16–17, 18–19,
20–21, 22–23, 24–25: western blot analysis of the purified recombinant ABC, BPP, PPP, PL, and CHP with convalescent sera of rabbits before and
after infection with B. bronchiseptica HB, respectively
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Furthermore, PPP and PL induced protective immunity
against virulent B. bronchiseptica HB in mice.
PPP is an outer membrane porin protein, also known
as a channel protein or protein matrix, found in Gram-
negative bacteria [10]. Outer membrane porin proteins
are highly conserved and can be used for species identi-
fication. They display good immunogenicity, making
them potential candidates for protective antigens [11, 12].
Previous research supports the hypothesis that porins are
good potential subunit vaccine candidates. Mice im-
munized with purified porin proteins were shown to be
resistant to Pseudomonas aeruginosa [10]. Research using
murine models showed that denatured forms of the re-
combinant outer membrane porin proteins OmpC, OmpF,
and OmpL from Salmonella enterica ssp. Typhi were im-
munogenic [13–15]. In contrast, another study indicated
that, despite their strong immunogenicity, these porin
proteins are not suitable vaccine candidates in their dena-
tured form; however, a combination of the three recom-
binant proteins conferred protection [16]. Recombinant
OmpF (a channel protein) from Aeromonas hydrophila
was also reported to have potential as a vaccine candidate,
because it could induce a Th1-type immune response.
Our results show that rPPP, a novel target antigen derived
from an outer membrane porin in B. bronchiseptica, can
stimulate splenocytes in vitro and elicits humoral and
cellular immune responses to confer significant pro-
tection in mice against challenge by a virulent strain of
B. bronchiseptica.
PL was identified as a lipoprotein in our previous
study. Lipoproteins abound in the outer membranes
of Gram-negative bacteria and have long been consid-
ered potential target antigens for vaccine development.
Hatfaludi et al. screened 71 Pasteurella multocida pro-
teins and found that only the outer membrane lipoprotein
plpE could produce a protective immune response in a de-
natured state [17]. Another recent analysis suggested that
recombinant VacJ lipoprotein from P. multocida is a puta-
tive vaccine candidate [18]. Our results are the first to
demonstrate the immunogenicity and protective efficacy
of a putative outer membrane lipoprotein from B. bronchi-
septica. IgG-subtype and cytokine analysis demonstrated
Fig. 3 Antibody response elicited after immunization with recombinant proteins or mock-vaccinated (PBS control) before challenge. a Histogram
indicating the recombinant protein specific serum antibody titers (total IgG) of sera collected from all mice 28 days after first immunization.
b Histogram indicating the recombinant protein specific serum antibody titers (subtypes IgG1and IgG2a) of sera collected from the mice
immunized with rPL, rPPP, and PBS controls at 28 days after first immunization. Data are presented as the mean optical density obtained from ELISA
analysis of individual serum samples (n = 8 per treatment) at a 1:200 dilution. The curve of antibody response was drawn where the ordinate axis
represents the absorbance at 450 nm ± standard deviation. * indicates highly significant differences compared with the mice immunized
with PBS (P < 0.001)
Fig. 4 Protective efficacy of recombinant proteins in the mouse
model. The percentage survival curve showing survival pattern of
immunized and control mice (8 mice/group) following challenge
with 1.74 × 107 cfu/mL B. bronchiseptica HB, respectively
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that rPL induced humoral and cell-mediated immune re-
sponses in mice and that Th2-type immunity dominates
response profile. Th2- type responses have higher levels of
IL-10 and produce more IgG1 [19–21]. In the present
study, rPL responses have higher levels of IL-10 and pro-
duce more IgG1,induced a stronger Th2-type response
compared to rPPP. The most direct way to evaluate a vac-
cine candidate is to measure the survival rate of vacci-
nated mice challenged with the lethal pathogen. In this
study, an effective degree of protection was observed
when mice were immunized with rPL compared with con-
trols, suggesting that rPL is an effective vaccine candidate.
Leu/ile/val-binding protein is a component of the leu-
cine, isoleucine, valine, threonine transport system. This
system is one of two periplasmic binding-protein-
dependent transport systems used for the high-affinity
transport of the branched-chain amino acids. Leu/ile/
val-binding proteins isolated from Bordetella pertussis,
Shigella flexneri, and Brucella abortus have been shown
to be highly immunogenic [22–24]. Putative amino acid
ABC transporter substrate-binding protein belongs to
the ATP-binding cassette (ABC) system, which generally
functions to import or export amino acids. ABC systems
are versatile, ATP-dependent transport systems for mol-
ecules ranging from small inorganic ions to large pro-
teins [25, 26]. ABC systems play important roles in
pathogen survival and pathogenicity and have been
identified as potential vaccine targets [27]. We cloned
and expressed recombinant leu/ile/val-binding protein,
amino acid ABC transporter substrate-binding protein,
and another conserved hypothetical protein and found
that each protein induced high antibody titers but could
not elicit significant protective immunity, at least indivi-
dually in denatured form. A highly immunogenic protein
is not necessarily the immune protective protein. For ex-
ample, the Leishmania HSP20 is antigenic during natural
infections, but as DNA vaccine, it does not protect BALB/
c mice against experimental L. amazonensis infection [28].
Furthermore, the results showed here also do not preclude
a possible use of the proteins within a multivalent vac-
cine. In particular, a vaccine combination can induced
a better protection [16, 29, 30].
Conclusion
In conclusion, this study shows that rPPP and rPL can
induce protective humoral and cellular immune responses
against B. bronchiseptica. These data suggest that rPPP
and rPL are potential immunomodulators or vaccine can-
didates if different vaccination approaches such as prime-
and-boost vaccination or multivalent subunit vaccines are
followed.
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